Abacus dx is pleased to announce the newest addition to Streck’s trusted blood collection tube portfolio, RNA Complete BCT™.
Biocartis is pleased to announce the launch of the Idylla™ ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy version of the solid biopsy Idylla™ EGFR Mutation Test (CE-IVD).
With over two million new cases of breast cancer diagnosed worldwide in 2018, breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. What else can be done to improve lab workflow and confidence in your results?
Abacus dx is pleased to announce the release of the latest probe from ZytoVision, ZytoLight® SPEC GATA2/MECOM Dual Color Fusion Probe.
Abacus dx is pleased to announce the launch of the new LymphoTrack B-cell Low Positive Controls and LymphoQuant B-cell Internal Controls as part of Invivoscribe’s MRD B-Cell Bundled Solution.
Abacus dx is pleased to announce our exclusive distribution of the Streck Cell Stabilisation product range in New Zealand. Included in this product range is the Cell-Free DNA BCT, otherwise known as the “Streck Tube”.
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
Abacus dx would like to update you with the latest product from Asuragen.
For all liquid biopsies, remember to use the “Streck Tube”, the No.1 tube worldwide for stabilisation of cell free DNA.